• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    1/8/24 8:05:59 AM ET
    $AIMD
    $AMAM
    $AMPE
    $AXNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AIMD alert in real time by email

    Gainers

    • Harpoon Therapeutics (NASDAQ:HARP) stock increased by 110.9% to $22.25 during Monday's pre-market session. The company's market cap stands at $376.7 million.
    • Ambrx Biopharma (NASDAQ:AMAM) stock rose 101.76% to $27.5. The market value of their outstanding shares is at $1.7 billion.
    • Vincerx Pharma (NASDAQ:VINC) shares moved upwards by 52.54% to $1.8. The company's market cap stands at $38.4 million.
    • Ampio Pharmaceuticals (AMEX:AMPE) stock rose 27.52% to $2.27. The company's market cap stands at $1.8 million.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock increased by 25.7% to $3.13. The market value of their outstanding shares is at $3.1 million.
    • Axonics (NASDAQ:AXNX) shares rose 20.91% to $69.61. The company's market cap stands at $3.5 billion.

    Losers

    • LumiraDx (NASDAQ:LMDX) shares decreased by 32.6% to $0.02 during Monday's pre-market session. The company's market cap stands at $7.4 million.
    • Sharps Technology (NASDAQ:STSS) shares fell 15.43% to $0.38. The company's market cap stands at $5.8 million.
    • Ainos (NASDAQ:AIMD) stock fell 12.41% to $2.4. The company's market cap stands at $11.2 million.
    • Biofrontera (NASDAQ:BFRI) stock fell 8.52% to $2.58. The company's market cap stands at $3.9 million.
    • Elevation Oncology (NASDAQ:ELEV) shares decreased by 8.32% to $0.8. The market value of their outstanding shares is at $34.0 million.
    • Cytokinetics (NASDAQ:CYTK) stock decreased by 8.25% to $86.0. The company's market cap stands at $8.4 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AIMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIMD
    $AMAM
    $AMPE
    $AXNX

    CompanyDatePrice TargetRatingAnalyst
    Cytokinetics Incorporated
    $CYTK
    1/28/2026$87.00Overweight
    Barclays
    Cytokinetics Incorporated
    $CYTK
    12/18/2025$95.00Neutral → Buy
    Goldman
    Cytokinetics Incorporated
    $CYTK
    7/30/2025Mkt Perform
    Raymond James
    Cytokinetics Incorporated
    $CYTK
    4/24/2025$55.00Overweight
    Barclays
    Elevation Oncology Inc.
    $ELEV
    3/24/2025$5.00 → $1.00Overweight → Equal-Weight
    Stephens
    Elevation Oncology Inc.
    $ELEV
    3/21/2025$1.00Outperform → Market Perform
    Leerink Partners
    Elevation Oncology Inc.
    $ELEV
    3/21/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Elevation Oncology Inc.
    $ELEV
    3/21/2025$0.70Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $AIMD
    $AMAM
    $AMPE
    $AXNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Cytokinetics with a new price target

    Barclays resumed coverage of Cytokinetics with a rating of Overweight and set a new price target of $87.00

    1/28/26 7:16:37 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics upgraded by Goldman with a new price target

    Goldman upgraded Cytokinetics from Neutral to Buy and set a new price target of $95.00

    12/18/25 8:41:18 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Cytokinetics

    Raymond James resumed coverage of Cytokinetics with a rating of Mkt Perform

    7/30/25 7:32:47 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AMAM
    $AMPE
    $AXNX
    SEC Filings

    View All

    Biofrontera Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Biofrontera Inc. (0001858685) (Filer)

    3/9/26 9:20:28 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Cytokinetics Incorporated

    S-8 - CYTOKINETICS INC (0001061983) (Filer)

    2/26/26 5:35:35 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Cytokinetics Incorporated

    10-K - CYTOKINETICS INC (0001061983) (Filer)

    2/26/26 4:01:01 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AMAM
    $AMPE
    $AXNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

    WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Busi

    3/9/26 5:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

    • Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz® PDT versus vehicle • 3-hour incubation regimen identified as the most promising protocol for further clinical development • Acne vulgaris represents a promising potential future indication for Ameluz®, significantly broadening the Company's dermatology pipeline WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced results of its Phase 2b clinical trial evaluating Ameluz® (aminolevulinic acid HCL) topical gel, 1

    3/9/26 9:15:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics to Participate in March Investor Conferences

    SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in the following investor conferences in March: Leerink 2026 Global Healthcare Conference: Fireside chat on Monday, March 9, 2026 at 9:20 AM Eastern Time in Miami Beach, FL.Citizens 2026 Life Sciences Conference: Fireside chat on Tuesday, March 10, 2026 at 9:00 AM Eastern Time in Miami Beach, FL.2026 Jefferies Biotech on the Beach Summit: One-on-one meetings on Wednesday, March 11, 2026 in Miami Beach, FL.Barclays 28th Annual Global Healthcare Conference: Fireside chat on Wednesday, March 11, 2026 at 2:30 PM E

    3/2/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AMAM
    $AMPE
    $AXNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ruemler Timothy James increased direct ownership by 294% to 40,218 units (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:45:47 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Crescenzo Andrew R. bought $256,400 worth of Option (40,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:34 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Director Monroe Jason L. bought $512,800 worth of Option (80,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:36 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $AIMD
    $AMAM
    $AMPE
    $AXNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Cytokinetics Incorporated

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    3/10/26 6:05:24 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Cytokinetics Incorporated

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    3/10/26 6:03:12 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Cytokinetics Incorporated

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    3/10/26 6:00:51 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AMAM
    $AMPE
    $AXNX
    Leadership Updates

    Live Leadership Updates

    View All

    Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

    "On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans

    1/27/26 8:00:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Names Jim Daly to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company's Board of Directors. "Jim has longstanding expertise leading commercial launches of innovative therapies, coupled with extensive Board experience guiding later-stage, global biopharma companies," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "We are pleased to welcome him to our Board and look forward to his contributi

    8/20/25 7:30:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

    Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jones as Chief Commercial Officer (CCO), starting August 25, 2025. In this role, Mr. Jones will oversee the Company's commercial functions, including sales, marketing, and market access. He will report directly to CEO Dr. Hermann Luebbert. This strengthening of the Company's management follows the recent announcement of an agreement to acquire all rights and assets related to Ameluz® and RhodoLED® for the US market, including the FDA approval and al

    8/11/25 4:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AMAM
    $AMPE
    $AXNX
    Financials

    Live finance-specific insights

    View All

    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

    WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Busi

    3/9/26 5:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

    MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance;~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the fourth quarter and full year of 2025. The company also provided full year 2026 financial guidance. "The fourth qu

    2/24/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com or directly at the following link: Cytokinetics Q4 2025 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics'

    2/12/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AMAM
    $AMPE
    $AXNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    11/27/24 6:08:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 7:50:19 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 7:21:58 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care